Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.34 |
| ▸ | PGD | P52209 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3020429 | 0.88 | LMNA (0.46) | LMNACYP2C19HIF1ASMN1; SMN2 | |
| SCHEMBL3026389 | 0.88 | POLB (0.42) | LMNAPOLBMAPK1ABCB1PGD | |
| SCHEMBL9356454 | 0.85 | LMNA (0.48) | LMNACYP2C19HIF1ASMN1; SMN2 | |
| SCHEMBL3019886 | 0.85 | LMNA (0.39) | LMNACYP2C19HIF1APOLBMAPK1 | |
| SCHEMBL711738 | 0.85 | POLB (0.35) | LMNAPOLBMAPK1ABCB1PGD | |
| SCHEMBL3030371 | 0.84 | LMNA (0.49) | LMNACYP2C19HIF1APOLBMAPK1 | |
| SCHEMBL3024742 | 0.84 | POLB (0.40) | LMNAPOLBMAPK1PGDTDP1 | |
| SCHEMBL9451103 | 0.81 | LMNA (0.59) | LMNACYP2C19HIF1ASMN1; SMN2 | |
| SCHEMBL9352729 | 0.81 | LMNA (0.59) | LMNACYP2C19HIF1ASMN1; SMN2 | |
| SCHEMBL3029790 | 0.80 | POLB (0.36) | LMNAPOLBMAPK1PGDTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2200971-B1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2013-04-24 | — | — | EP | disclosed |
| EP-2200655-B1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2012-07-18 | — | — | EP | disclosed |
| US-20100221192-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-09-02 | — | — | US | disclosed |
| US-20100221192-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-09-02 | — | — | US | disclosed |
| US-20100221192-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-09-02 | — | — | US | disclosed |
| US-20100209356-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-08-19 | — | — | US | disclosed |
| US-20100209356-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-08-19 | — | — | US | disclosed |
| US-20100209356-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-08-19 | — | — | US | disclosed |
| US-20100189656-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-07-29 | — | — | US | disclosed |
| US-20100189656-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-07-29 | — | — | US | disclosed |
| US-20100189656-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-07-29 | — | — | US | disclosed |
| EP-2200971-A1 | CONTRAST AGENTS | GE Healthcare AS (NO) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009047316-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100189656-A1 | CONTRAST AGENTS | IPO4, TPO, IPO11 | LMNA 1835/4885CYP2C19 4234/4885HIF1A 1213/4885 |
| US-20100209356-A1 | CONTRAST AGENTS | C5, C1S, C1R | LMNA 2073/4885CYP2C19 2427/4885HIF1A 509/4885 |
| US-20100221192-A1 | CONTRAST AGENTS | C5, C1S, C1R | LMNA 1840/4885CYP2C19 2570/4885HIF1A 1051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.